» Articles » PMID: 22033480

Structure-based Design of a Protein Immunogen That Displays an HIV-1 Gp41 Neutralizing Epitope

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2011 Oct 29
PMID 22033480
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Antibody Z13e1 is a relatively broadly neutralizing anti-human immunodeficiency virus type 1 antibody that recognizes the membrane-proximal external region (MPER) of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Based on the crystal structure of an MPER epitope peptide in complex with Z13e1 Fab, we identified an unrelated protein, interleukin (IL)-22, with a surface-exposed region that is structurally homologous in its backbone to the gp41 Z13e1 epitope. By grafting the gp41 Z13e1 epitope sequence onto the structurally homologous region in IL-22, we engineered a novel protein (Z13-IL22-2) that contains the MPER epitope sequence for use as a potential immunogen and as a reagent for the detection of Z13e1-like antibodies. The Z13-IL22-2 protein binds Fab Z13e1 with a K(d) of 73 nM. The crystal structure of Z13-IL22-2 in complex with Fab Z13e1 shows that the epitope region is faithfully replicated in the Fab-bound scaffold protein; however, isothermal calorimetry studies indicate that Fab binding to Z13-IL22-2 is not a lock-and-key event, leaving open the question of whether conformational changes upon binding occur in the Fab, in Z13-IL-22, or in both.

Citing Articles

Bringing immunofocusing into focus.

Musunuri S, Weidenbacher P, Kim P NPJ Vaccines. 2024; 9(1):11.

PMID: 38195562 PMC: 10776678. DOI: 10.1038/s41541-023-00792-x.


Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.

Hurwitz J, Bonsignori M Viral Immunol. 2018; 31(2):124-132.

PMID: 29315059 PMC: 5915263. DOI: 10.1089/vim.2017.0144.


Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.

Molinos-Albert L, Clotet B, Blanco J, Carrillo J Front Immunol. 2017; 8:1154.

PMID: 28970835 PMC: 5609547. DOI: 10.3389/fimmu.2017.01154.


How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.

Pancera M, Changela A, Kwong P Curr Opin HIV AIDS. 2017; 12(3):229-240.

PMID: 28422787 PMC: 5557343. DOI: 10.1097/COH.0000000000000360.


Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.

Morris C, Azadnia P, de Val N, Vora N, Honda A, Giang E mBio. 2017; 8(1).

PMID: 28246356 PMC: 5347340. DOI: 10.1128/mBio.00036-17.


References
1.
Spolar R, Record Jr M . Coupling of local folding to site-specific binding of proteins to DNA. Science. 1994; 263(5148):777-84. DOI: 10.1126/science.8303294. View

2.
Arnold G, Velasco P, Holmes A, Wrin T, Geisler S, Phung P . Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol. 2009; 83(10):5087-100. PMC: 2682058. DOI: 10.1128/JVI.00184-09. View

3.
Esnouf R . Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr D Biol Crystallogr. 1999; 55(Pt 4):938-40. DOI: 10.1107/s0907444998017363. View

4.
Pancera M, McLellan J, Wu X, Zhu J, Changela A, Schmidt S . Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol. 2010; 84(16):8098-110. PMC: 2916520. DOI: 10.1128/JVI.00966-10. View

5.
Hessell A, Rakasz E, Poignard P, Hangartner L, Landucci G, Forthal D . Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009; 5(5):e1000433. PMC: 2674935. DOI: 10.1371/journal.ppat.1000433. View